• Grand Pharmaceutical proposes replacing HLB Hodgson Impey Cheng with Deloitte Touche Tohmatsu for the year ending Dec. 31, 2026.
• The switch requires shareholder approval at a special general meeting and aims to support overseas expansion through broader international audit coverage.
• Deloitte's proposed audit fee is approximately HK$ 4.38 million, compared with HK$ 4.35 million paid to HLB for 2025.
• The board and audit committee reported no disagreements or unresolved audit matters with HLB.
• HLB has not started the audit; the proposed change is not expected to materially affect the annual audit or results release.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261022-12380412), on October 22, 2026, and is solely responsible for the information contained therein.